The gene therapy market is projected to grow at an annualized rate of 45%, till 2030

ALTADENA, Calif. - July 24, 2020 - PRLog -- To order this 670+ page report, which features 190+ figures and 340+ tables, please visit this link

Key Market Insights

§  In the past four years, more than 31,000 patents related to gene therapies and gene editing have been filed / granted; this is indicative of the heightened pace of research in this domain

§  Presently, there are more than 10 approved gene therapies; over 465 product candidates are being evaluated for the treatment of a variety of disease indications

§  Most of the therapeutic leads are in the early stages of clinical development; a variety of viral and non-viral vectors are being used to introduce different types of gene modifications in such therapies

§  Although start-ups and mid-sized companies are spearheading the innovation, several big biopharmaceutical companies are also actively engaged

§  With multiple approved products and several under development, price is one of the major concerns in this market; the future is likely to witness the establishment of more affordable pricing and reimbursement strategies

§  As several candidates progress towards approval, developers are exploring diverse commercialization strategies to be implemented across different stages of a product's launch cycle

§  CMOs offering vector manufacturing services have become an integral part of the gene therapy supply chain, owing to their ability to overcome the various associated challenges

§  Several investors, having realized the untapped opportunity within this emerging segment of genetic disorders, have invested over USD 16.5 billion across 280 instances, in the period between 2014 and 2019

For more information, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

Table of Contents

1.         PREFACE
1.1.      Scope of the Report
1.2.      Research Methodology
1.3.      Chapter Outlines

2.         EXECUTIVE SUMMARY

3.         INTRODUCTION

3.1.      Context and Background

3.2.      Evolution of Gene Therapies

3.3.      Classification of Gene Therapies

3.3.1.    Somatic and Germline Gene Therapy

3.3.2.    Ex Vivo and In Vivo Gene Therapy

3.4.      Routes of Administration

3.5.      Mechanism of Action of Gene Therapies

3.6.      Concept of Gene Editing

3.7.      Advantages and Disadvantages of Gene Therapies

3.8.      Ethical and Social Concerns Related to Gene Therapies

3.9.      Future Constraints and Challenges Related to Gene Therapies

3.9.1.    Concerns Related to Therapy Development

3.9.2.    Concerns Related to Manufacturing

3.9.3.    Concerns Related to Commercial Viability

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com